podcast (1)

Biocon CMD Kiran Mazumdar-Shaw tells ET Now in an interview that the Company remains extremely confident of delivering very strong numbers in its Biologics business this fiscal, with a more robust performance in the second half of the year on the back of the commercialization of biosimilar Trastuzumab in the U.S. market.

She also talks about how the recently announced Mylan-Upjohn merger announcement augurs well for Biocon’s biosimilars business in China, given that Upjohn has a very strong presence in that country.

For more on Kiran Mazumdar-Shaw’s views on Biocon’s performance overall and Biologics in particular, click to listen to the #podcast

Audio Credit: ET Now

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s